Aquestive Therapeutics ( (AQST) ) has provided an announcement.
Aquestive Therapeutics has announced its plans to advance several product candidates through clinical development and potential FDA approval. The company’s pipeline includes Anaphylm, a sublingual film for epinephrine delivery, and AQST-108, a topical gel for alopecia areata. Additionally, the company is working on expanding market access for its epilepsy treatment, Libervant, despite challenges related to orphan drug exclusivity. These developments could significantly impact Aquestive’s market position and offer new treatment options for patients.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drug delivery systems. The company specializes in oral and sublingual film formulations, targeting unmet medical needs in areas such as epilepsy and anaphylaxis.
YTD Price Performance: -27.79%
Average Trading Volume: 1,691,932
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $262M
Learn more about AQST stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com